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Structure-based virtual screening for the 
discovery of allosteric modulators for  






In this chapter, we analyzed the structure of the complete energy-coupling factor (ECF) 
transporter for folate from Lactobacillus delbrueckii (the four subunits, EcfA, EcfA’, EcfT 
and S-component, FolT in this case) to identify an allosteric pocket in the energizing 
module (EcfAA’T). By structure-based virtual screening, we identified one compound 
that presumably binds to this allosteric pocket and it is able to inhibit folate uptake. 
According to the predicted binding mode, this compound binds in between the coupling 
helices of the EcfT subunit, at the interface with one of the EcfA domains. The ECF-FolT 
transporter belongs to group II in which several S-components, with different substrate 
specificities, make use of the same energizing module. Therefore, by interacting with the 
energizing module, this compound is able to inhibit the transport of several vitamins and 
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Until 2013, the mechanism of transport of energy-coupling factor (ECF) 
transporters was completely unknown. Since then, five crystal structures of 
complete transporters have been reported: the folate, the pyridoxin (although in 
the original publication it is described as the hydroxymethyl pyrimidine 
transporter) and the pantothenate ECF transporters from Lactobacillus brevis;1–3 
and the folate ECF transporter from Lactobacillus delbrueckii.4 These crystal 
structures allowed to propose a working model for transport (Chapter 1, 
Section 1.3.2).4 In all cases, the full-length ECF transporter was crystallized 
without substrate bound in the S-component. To describe the structure, here we 
will focus on the crystal structure of the folate-specific transporter ECF-FolT from 
L. delbrueckii (PDB ID: 5D7T)4 in the apo state, without folate or ATP bound, 
solved at a resolution of 3.0 Å (Figure 1). 
 
Figure 1. Structure of the ECF-FolT transporter from Lactobacillus delbrueckii. A) Surface 
representation, with EcfA and EcfA’ in light brown and orange, EcfT in teal, and the S-
component in gray. This color code is maintained throughout this chapter. The cytoplasmic and 
extracytoplasmic spaces are indicated as ‘In’ and ‘Out’, respectively. B) Same as A, but in ribbon 
representation, with the names of the helices of the EcfT subunit, to highlight the coupling 
helices CH1–3 of EcfT connecting the other three subunits (EcfA, EcfA’ and S-component) of 
the transporter. 
 
 In the crystal structure, the two ATPases (EcfA and EcfA’) are in the open 
conformation (there should be also a closed conformation in which ATP binds 
and it is hydrolyzed). The EcfT subunit can be divided into two parts: five 
transmembrane α-helices (TMH1–5) and three coupling helices (CH1–3). The 
transmembrane helices interact with the S-component, in this case FolT, and the 
coupling helices with the ATPase subunits. FolT is crystallized in the open 
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conformation, and its six helices lie parallel to the plane of the membrane, 
differently from the putative membrane orientation of FolT cocrystallized with 
folate, in which the helices are perpendicular to the membrane.4 According to the 
proposed mechanism, the S-component binds its substrate, and it is able to topple 
in the membrane to associate with the energizing module (EcfAA’T) by 
interaction with the EcfT subunit. The association of the S-component with EcfT 
disturbs the folate-binding pocket, which leads to substrate release into the 
cytoplasm. The coupling helices of EcfT (CH1–3 in Figure 1B) are responsible for 
the transmission of the conformational changes from the ATPases to the S-
component. 
 In this chapter, our goal was to identify an allosteric pocket in the 
energizing module of ECF-FolT, and to identify molecules that could bind in that 
pocket. Ideally, these molecules would be able to block the movement of the 
coupling helices of the EcfT subunit, therefore interfering with the 
communication between the ATPases and the S-component. Given that this ECF 
transporter belongs to group II, several S-components with different substrate 
specificities share the same energizing module. Therefore, with one single 
molecule, we would be able to block transport of all vitamins that are transported 
by the same energizing module. This is important because it would confirm the 
proposed mechanism of transport, and the new binders could be promising 
antibiotics, given that they would block the uptake of vitamins in pathogenic 
bacteria that rely on this type of transporters for survival. 
6.2 Results and discussion 
6.2.1 Prediction of druggable pockets in the ECF-FolT transporter 
Our goal was to identify a pocket formed, at least partially, by the coupling 
helices of the EcfT subunit of the transporter. The reason is that according to the 
proposed mechanism of transport, the conformational changes of these helices 
play an important role in the transport of vitamins by transferring the 
conformational changes of the ATPase subunits to the S-component. Ideally, we 
wanted to identify a pocket at the interface of these coupling helices of the EcfT 
subunit and one of the ATPase subunits. The other option would be to block the 
binding platform of EcfT where the S-component binds. Given that this occurs 
inside the membrane, it would presumably lead to very hydrophobic molecules 
that most probably would have solubility problems in aqueous media. 
 We used DoGSiteScorer,5,6 a fully automated algorithm, to identify 
pockets and predict their druggability. Druggability is the likelihood of finding 
a selective, low-molecular weight molecule that binds with high affinity to the 




ECF-FolT from L. delbrueckii (PDB ID: 5D7T)4 to DoGSiteScorer, and we obtained 
a list of thirty-six pockets, eleven of them considered druggable (Table 1).  
 Geometric and physicochemical properties of the predicted pockets were 
calculated by DoGSiteScorer, such as volume, surface, lipophilic surface and 
depth (Table 1). The program also provides a druggability score from 
0 (undruggable) to 1 (druggable). Druggable pockets tend to be larger, deeper, 
more hydrophilic and complex in shape. The average parameters for druggable 
pockets are: volume 900 Å3, depth 21 Å and lipophilic surface fraction 0.7; 
compared to those of undruggable pockets: volume 300 Å3, depth 13 Å and 
lipophilic surface fraction 0.6.6 Pockets with a druggability score ≥0.5 are 
considered druggable (Table 1). 
 
Table 1. Predicted druggable pockets by DoGSiteScorer. Main shape descriptors for each 
















P1 444 471 259 0.55 23 0.85 
P2 704 821 723 0.88 21 0.84 
P3 940 1165 647 0.56 26 0.83 
P4 1028 1115 714 0.64 19 0.81 
P5 639 1019 731 0.72 15 0.78 
P6 501 667 557 0.84 16 0.76 
P7 292 460 351 0.76 16 0.67 
P8 287 388 366 0.94 15 0.64 
P9 431 786 437 0.56 14 0.63 
P10 330 367 178 0.49 14 0.58 
P11 220 540 301 0.56 13 0.50 
 
 When we analyzed these eleven pockets (Figure 2), we observed that 
three of them (P3, P9 and P11) are located between the subunits EcfA and EcfA’ 
of the transporter, where the molecules of ATP bind and are hydrolyzed. The 
software also detected part of the folate-binding pocket (P10) in the S-component. 
Pocket P2 is in the EcfT subunit, and pockets P5, P6, P7 and P8 are at the interface 
of EcfT and the S-component. The remaining two pockets, P1 and P4, are located 
at the interface of EcfT and EcfA, and pocket P4 also included four residues of 
the S-component. These last two pockets are located in our region of interest. We 
selected pocket P4 because it involves residues of the three coupling helices of 
EcfT, which makes it an ideal pocket to inhibit vitamin transport. 




Figure 2. Structure of the ECF-FolT transporter and the eleven predicted druggable pockets: P1 
pink, P2 red, P3 dark blue, P4 yellow, P5 dark green, P6 orange, P7 purple, P8 brown, P9 light 
green, P10 light blue and P11 gray. 
 
6.2.2 Virtual screening on the ECF-FolT transporter 
We performed a structure-based virtual screening campaign on pocket P4 of the 
ECF-FolT transporter. Structure-based virtual screening has been successfully 
used in medicinal chemistry for the past twenty years.9,10 It is a computational 
technique that allows to identify hits from big libraries of compounds as potential 
binders of the target of interest. 
 For our virtual screening, we used the Express Collection of Princeton 
BioMolecular Research, and we filtered the library taking into account drug-like 
properties: we included compounds with a molecular weight of 250–500 g mol–1, 
and we removed fused aromatic tricyclic (or bigger) compounds and esters using 
MONA.11,12 We performed the virtual screening using the KNIME Analytics 
Platform.13,14 We docked the library using the X-ray crystal structure of the folate-
specific transporter ECF-FolT from L. delbrueckii (PDB ID: 5D7T)4 by using 
LeadIT15 in the identified pocket P4, generating ten poses for each compound and 
we filter the poses that had an estimated Gibbs free energy of binding better than 
–25 kJ mol–1. To avoid the identification of compounds that are frequent hitters 
or that may interfere with biochemical assays, we used the PAINS (Pan Assay 
INterference compoundS) filter16 and Eli Lilly rules17,18 to remove promiscuous 
and reactive compounds. After scoring the resultant poses with the scoring 
function HYDE in SeeSAR,19 we removed the compounds with red-flagged 
torsions (torsion angles that are rarely observed in crystal structures) and those 




binding affinity, we visually inspected the top-100 compounds in SeeSAR and 
we selected twelve compounds (Figure 3). 
 
Figure 3. Schematic representation of the virtual screening process. 
 
 The twelve compounds were selected in a way that the best 
representative compounds of each structural cluster was present, to avoid closely 




Figure 4. Eleven of the twelve compounds selected from the virtual screening campaign as 
potential modulators of the ECF-FolT transporter. The compounds are arranged according to 
their predicted binding affinity, from 1 (best predicted binding affinity) to 12. The structure of 
compound 11 cannot be disclosed at the moment as it may be patented.  
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 During the visual inspection using SeeSAR, we observed that the 
majority of these twelve compounds bind to the same part of the pocket P4, in 
contact with the coupling helix CH2 and the loop connecting CH3 with TMH5 of 
EcfT, at the interface with EcfA (Figure 5). A few compounds bind only to the 
EcfT subunit by interaction with the helix CH1 and the same loop, connecting 




Figure 5. A) Predicted binding mode of eleven compounds selected from the virtual screening 
campaign, with all the subunits of the transporter in surface representation. B) Close-up of the 
binding pocket P4 in surface representation. C) Close-up of the binding pocket P4 in surface 
(EcfA, EcfA’ and S-component) and ribbon (EcfT) representation. 
 
6.2.3 Transport-activity assays 
We evaluated the twelve selected compounds as modulators of folate uptake 
with a transport-activity assay. We reconstituted the ECF-FolT transporter into 
proteoliposomes and performed transport assays using radiolabeled folate 
(Figure 6). Due to solubility problems with some of the compounds, we only 
report here the compounds that were perfectly soluble under the conditions of 
the assay (i.e., compounds 6, 11 and 12 at a concentration of 5 mM, in buffer pH 7.5 
with 5% (v/v) of DMSO). We observed that compounds 6 and 12 present uptake 
rates similar to the experiment in the presence of only DMSO. Compound 11, 
however, was able to inhibit folate uptake. In case of the ECF-FolT in the presence 
of DMSO only, the uptake rate is 0.62 pmol min–1 μg–1 ECF-FolT, while in the 
presence of compound 11, the uptake rate is 0.12 pmol min–1 μg–1 ECF-FolT, 





Figure 6. Transport-activity assay. A) Schematic representation of the assay, with the ECF-FolT 
reconstituted into a proteoliposome. B) Transport activity of ECF-FolT with 5% (v/v) of DMSO 
only (black), and with compounds 6 (blue), 11 (red) and 12 (green), at a concentration of 5 mM. 
The error represents the standard deviation of three experiments. 
 
 As mentioned above, ECF-FolT belongs to group II ECF transporters. 
Therefore, the same energizing module (EcfAA’T) is shared by several S-
components. In the case of L. delbrueckii, eight different S-components share the 
same energizing module. In order to prove that compound 11 is an allosteric 
inhibitor, we performed a transport assay with ECF-PanT from L. delbrueckii, 
which has the same energizing module and a different S-component, PanT, for 
the transport of pantothenate (vitamin B5). Given that compound 11 is predicted 
to bind in the pocket P4, located in the energizing module, it should also inhibit 
the transport of pantothenate. We performed the uptake assay of radiolabeled 
pantothenate by ECF-PanT reconstituted in proteoliposomes in the same 
conditions as in the case of ECF-FolT, and we observed that compound 11 is also 
an inhibitor of pantothenate uptake (Figure 7A). In order to confirm that 
compound 11 is selective for ECF transporters, and that its effect is not due to an 
artifact in the assay, we performed a control experiment with a classical ABC 
transporter. We used the glycine betaine transporter OpuA from Lactococcus lactis 
and we measured the transport in the absence and presence of compound 11, 
using the same conditions for the assay as in the case of the ECF transporters. We 
observed that the uptake of radiolabeled glycine betaine by OpuA was not 
affected by the presence of compound 11 (Figure 7B), confirming in this way that 
this compound is an allosteric inhibitor selective for ECF transporters. 
 




Figure 7. A) Transport activity of ECF-PanT with 5% (v/v) of DMSO only (black) and with 
compound 11 (red) at a concentration of 5 mM. B) Transport activity of OpuA with 5% (v/v) of 
DMSO only (black) and with compound 11 (red) at a concentration of 5 mM. The error 
represents the standard deviation of two and three experiments, for A) and B) respectively. 
 
 Based on these results, we propose that compound 11 binds to the 
allosteric pocket of the energizing module blocking the movement of the 
coupling helices of the EcfT subunit. According to the proposed mechanism of 
transport of ECF transporters (Chapter 1, Section 1.3.2), compound 11 would 
stabilize state B (Figure 8) in the transport cycle, avoiding in this way the scissor-
like movement of the coupling helices that would dissociate the S-component 
from the energizing module (state C). 
 
 
Figure 8. Schematic representation of the proposed mode of inhibition of compound 11. Color 
code: EcfA and EcfA’ in red; EcfT with its coupling helices in blue; S-component in gray; 






We have identified a druggable pocket in the energizing module (EcfAA’T) of 
the ECF-FolT transporter of L. delbrueckii, by using DoGSiteScorer. The 
energizing module is common for the transport of several vitamins, given that 
various S-components bind to it to form a complete transporter. By structure-
based virtual screening we have identified potential modulators of the 
transporter that are predicted to bind in the newly identified pocket. We have 
shown that compound 11 is able to inhibit folate uptake. Compound 11 is an 
allosteric inhibitor because it is also able to inhibit pantothenate uptake by ECF-
PanT from the same organism, and it is selective for ECF transporters, given that 
it does not affect transport by a completely unrelated ABC transporter, OpuA 
from L. lactis. Compound 11 probably blocks the movement of the coupling 
helices of the EcfT subunit that transfers the conformational changes from the 
ATPases to the S-component. Considering the proposed mechanism of transport 
of ECF transporters, we suggest that compound 11 stabilizes the energizing 
module in a way that blocks the movement of the coupling helices, therefore 
avoiding the release of the S-component, and making the energizing module 
ineffective. Given that the energizing module is present in limiting amounts in 
the cell, compound 11 is a useful hit for the development of antibiotics. 
Cocrystallization of the ECF-FolT transporter in complex with compound 11 
would confirm the predicted binding mode and set the stage for further 
optimization. 
6.4 Experimental section 
6.4.1 Prediction of druggable pockets 
The DoGSitScorer5,6,20 server was used to identify pockets and predict their 
druggability. The X-ray crystal structure of the folate-specific transporter ECF-
FolT from L. delbrueckii (PDB ID: 5D7T)4 was used, selecting chains A, B, C and D 
from the PDB. DoGSiteScorer was customized to work on the pocket level, with 
the druggability estimation for pockets option switched on. The descriptor 
information for pocket P4 is shown in Table 2. 
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Size and shape descriptors Amino acid descriptors 
Volume (Å3) 1027.85 # Ala 2 
Surface (Å2) 1114.93 # Arg 5 
Lipophilic surface (Å2) 713.60 # Asn 0 
Depth (Å) 18.51 # Asp 2 
Ellipsoid main axis ratio c/a 0.23 # Cys 0 
Ellipsoid main axis ratio b/a 0.59 # Gln 0 
Enclosure 0.11 # Glu 3 
Functional-group descriptors # Gly 2 
# Hydrogen-bond donors 21 # His 0 
# Hydrogen-bond acceptors 61 # Ile 4 
# Metals 0 # Leu 6 
# Hydrophobic interactions 28 # Lys 0 
Hydrophobicity ratio 0.25 # Met 2 
Element descriptors # Phe 3 
# Pocket atoms 204 # Pro 3 
# Carbons 139 # Ser 3 
# Nitrogens 30 # Thr 1 
# Oxygens 34 # Trp 1 
# Sulfurs 1 # Tyr 2 
# Other elements 0 # Val 3 
Amino acid composition # special amino 
acids 
0 
Apolar amino acid ratio 0.57 
Polar amino acid ratio 0.19 
 Positive amino acid ratio 0.12 
Negative amino acid ratio 0.12 
 
6.4.2 Virtual screening 
The Express Collection of Princeton BioMolecular Research, Inc. 
(http://www.princetonbio.com/, downloaded in May 2015) was used for the 
virtual screening campaign and was filtered first in MONA11,12 according to the 
following criteria: molecular weight 250–500 g mol–1; fused aromatic tricyclic (or 
bigger) compounds and esters were removed. Virtual screening was done using 
the KNIME Analytics Platform13 and the interfaces for KNIME available from 
BioSolveIT.14 After generation of the 3D coodinates by the 3D generator interface 
from BioSolveIT,14 the library was docked as follows: the X-ray crystal structure 
of the folate-specific transporter ECF-FolT from L. delbrueckii (PDB ID: 5D7T)4 
was used for docking by using LeadIT (version 2.1.8) from BioSolveIT.15 The 
receptor was defined by manual selection and included the following amino acid 




Ile74 from the S-component; Pro132–Thr169 and Leu218–Leu239 from EcfT. The 
default settings were used for docking. Ten poses of each molecule were 
generated, filtered based on the calculated [Total Score] (–25 kJ mol–1 was used 
as cutoff, poses with a higher [Total Score] were discarded) and promiscuous and 
toxic compounds were removed using the PAINS filter16 and Eli Lilly rules.17,18 
The resultant poses were scored with HYDE in SeeSAR (version 3.2),19 and all 
poses with red-flagged torsions and compounds with only one pose were 
removed. From the top-1000 poses according to the estimated affinity, the top-
100 compounds were visually inspected in SeeSAR.19 The ones with at least two 
similar poses were selected as potential candidates for screening. The best 
representative of each cluster of structurally similar compounds (twelve 
compounds in total) were purchased from Princeton BioMolecular Research, Inc. 
 
6.4.3 Expression of ECF-FolT and membrane vesicle preparation 
Expression of ECF-FolT was performed in a 5 L flask containing 2 L of Yeast 
Trypton medium (Bacto trypton (8 g L–1), Bacto yeast extract (5 g L–1), NaCl 
(2.5 g L–1)), supplemented with potassium phosphate buffer (KPi, pH 7.0, 2.5 mM), 
glycerol (0.5%) and ampicillin (100 µg mL–1). The Escherichia coli MC1061 cells 
with p2BAD His10-ECF-FolT-STREPII were grown at 37 °C, 200 rpm to an OD600 
of 0.8, after which the temperature was reduced to 25 °C. After allowing the 
cultures to cool down for 20 min, expression was induced by addition of 
arabinose (1.0·10–2%). After 3 h of expression, the cells were harvested by 
centrifugation (15 min, 7,446 x g, 4 °C), washed in buffer A (KPi, pH 7.5, 50 mM) 
and resuspended in buffer B (KPi (pH 7.5, 50 mM), glycerol (10%)). Membrane 
vesicles were either prepared immediately, or the resuspended cells were stored 
at –80 °C after flash freezing in liquid nitrogen. 
 Before membrane-vesicle preparation, MgSO4 (1 mM) and DNase (~50–
100 µg mL–1) were added to the cells. The cells were lysed by high-pressure 
disruption (Constant Cell Disruption System Ltd, UK, two passages at 25 kPsi for 
E. coli cells or at 39 kPsi for L. lactis cells, 5 °C), and cell debris was removed by 
low-speed centrifugation (30 min, 12074 x g, 4 °C). Membrane vesicles were 
collected by ultracentrifugation (120 min, 193,727 x g, 4 °C), and resuspended in 
buffer B to a final volume of 5 mL per 1 L of cell culture. Subsequently, the 
membrane vesicles were aliquoted, flash frozen in liquid nitrogen and stored at 
–80°C. The total protein concentration in the membrane vesicles was determined 
by Bradford Protein Assay (Bio-Rad).4 
 
6.4.4 Protein purification 
For the purification of ECF-FolT, membrane vesicles were thawed rapidly and 
solubilized in buffer C (KPi (pH 7.5, 50 mM), NaCl (300 mM), imidazole (15 mM), 
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n-dodecyl-β-D-maltopyranoside (DDM, Anatrace, 1%, w/v)) at 4 °C for 1 h, while 
gently rocking. Insolubilized material was removed by centrifugation (20 min, 
442,907 x g, 4 °C). The supernatant was incubated at 4 °C for 1 h under gentle 
rocking with nickel-sepharose resin (column volume = 0.5 mL), which had been 
equilibrated with buffer D (KPi (pH 7.5, 50 mM), NaCl (300 mM), imidazole 
(50 mM), DDM (0.05%, w/v)). Subsequently, the suspension was poured into a 
10 mL disposable column (BioRad), and the flow through was collected. The 
column material was washed with buffer D (15 mL). The ECF-FolT complex was 
eluted in three fractions of buffer E (KPi (pH 7.5, 50 mM), NaCl (300 mM), 
imidazole (500 mM), DDM (0.05%, w/v)) of 400 µL, 750 µL and 500 µL, 
respectively. EDTA (1 mM) was added to the second elution fraction to remove 
co-eluted nickel cations. Subsequently, the second elution fraction was purified 
by size-exclusion chromatography using a Superdex 200 10/300 gel filtration 
column (GE Healthcare), equilibrated with buffer F (KPi (pH 7.5, 50 mM), NaCl 
(150 mM), DDM (0.05%, w/v)). After size-exclusion chromatography, the 
fractions containing the ECF-FolT complex were combined and used directly for 
reconstitution. 
 
6.4.5 Reconstitution into proteoliposomes 
Purified ECF-FolT was reconstituted in proteoliposomes as described 
previously,41 using a protein to lipid ratio of 1:250 (w/w) and using liposomes 
composed of E. coli polar lipids and egg phosphatidylcholine (3:1 (w/w) ratio). 
 
6.4.6 Radiolabeled-folate transport assay 
In order to use the proteoliposomes in the transport assay, they were thawed, 
and MgATP (5 mM) and compounds 1–12 (5 mM, to a final concentration of 5% of 
DMSO) were added. To include these compounds in the proteoliposomes, three 
cycles of flash-freezing in liquid nitrogen and quick thawing of the 
proteoliposomes were performed. Subsequently, the proteoliposomes were 
extruded through a 400 nm pore size polycarbonate filter (Avestin, eleven 
passages). To wash away the external nucleotides, the proteoliposomes were 
diluted 32 times to a final volume of 8 mL. After centrifugation (45 min, 
285,775 x g, 4 °C), the proteoliposomes were resuspended in buffer A to a final 
concentration of 0.5–1 µg ECF-FolT µL–1. For each time point in the transport 
assays, a reaction volume of 200 µL of buffer A supplemented with [3, 5, 7, 9-3H]- 
folic acid (5 nM) and non-radiolabeled folic acid (95 nM) was incubated at 25 °C 
while being stirred. Transport was started by adding 1 µg of ECF-FolT 
reconstituted in proteoliposomes. At the indicated time point, 2 mL of stop buffer 
(ice-cold buffer A) was added, and the reaction was rapidly filtered over a BA-85 




filter was dried at 80 °C for 1 h. Subsequently, the filter was dissolved in 5 mL of 
Filter Count scintillation liquid (PerkinElmer) and the levels of radioactivity were 
determined using a PerkinElmer Tri-Carb 2800 TR isotope counter. 
 
6.4.7 Expression, purification and reconstitution of ECF-PanT in 
proteoliposomes, and radiolabeled uptake assay 
The genes encoding ECF-PanT from L. delbrueckii subsp. bulgaricus 
(LDB_RS01805, ecfA; LDB_RS01810, ecfA’; LDB_RS01815, ecfT; LDB_RS01970, 
panT) were cloned in the p2BAD vector in the same way as described for ECF-
FolT,4,22 and this vector was transformed into Ca2+-competent cells of the E. coli 
strain MC1061. The expression, purification and reconstitution of ECF-PanT in 
proteoliposomes were performed as described for ECF-FolT, with the only 
differences being the concentration of L-arabinose used for induction (1.0*10-3% 
(v/v) of L-arabinose for expression of ECF-PanT instead of 1.0*10-2% (v/v)) and 
the protein to lipid reconstitution ratio (1:1000 for ECF-PanT instead of 1:250). 
The radiolabeled uptake assay was performed as described for ECF-FolT, with L-
[2,3-3H]pantothenic acid (5 nM) and  non-radiolabeled pantothenic acid (95 nM) 
present in the assay buffer instead of the radiolabeled and non-radiolabeled 
folate. Transport was started by addition of 0.25 µg of ECF-PanT (instead of 1 µg 
of ECF-FolT) and uptake was followed for 8 min. 
 
6.4.8 Expression, purification and reconstitution of OpuA in 
proteoliposomes, and radiolabeled uptake assay 
The expression, purification and reconstitution of OpuA in proteoliposomes was 
performed as described elsewhere, using a protein to lipid reconstitution ratio of 
1:100.21,23 The radiolabeled uptake assay was performed as described 
previously,24 by loading the proteoliposomes with MgATP (5 mM) instead of the 
ATP-regenerating system. Additionally, the proteoliposomes were loaded with 
5% (v/v) of DMSO, compound 11 (5 mM, to a final concentration of 5% of DMSO), 
or an equivalent volume of buffer. Encapsulation of the chemicals was achieved 
by performing five freeze-thaw cycles, followed by two washing steps with KPi 
(pH 7.0, 50 mM), after which the proteoliposomes were resuspended to a final 
OpuA concentration of about 80 mg mL–1. For the uptake assay, the 
proteoliposomes were diluted to a final OpuA concentration of 5 mg mL–1 in KPi 
(pH 7.0, 46.9 mM), KCl (499.7 mM), [14C]-glycine betaine (4.8 µM), non-
radiolabeled glycine betaine (14.9 µM), and uptake was followed for 5 min. 
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6.5 Contributions from co-authors 
Dr. M. Jäger assisted during the virtual screening. The biochemical experiments 
were performed by L. J. Y. M. Swier, W. K. Stanek and H. Sikkema, from the 
group of Prof. D. J. Slotboom. 
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